{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T01:30:44Z","timestamp":1793323844120,"version":"4.5.0"},"reference-count":136,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010040","name":"Taishan Scholar Project of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010040","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Aging Neurosci."],"abstract":"<jats:p>Alzheimer's disease (AD) is an irreversible, progressive neurodegenerative brain disorder with no effective therapeutic drugs currently. The complicated pathophysiology of AD is not well understood, although beta-amyloid (A\u03b2) cascade and hyperphosphorylated tau protein were regarded as the two main causes of AD. Other mechanisms, such as oxidative stress, deficiency of central cholinergic neurotransmitters, mitochondrial dysfunction, and inflammation, were also proposed and studied as targets in AD. This review aims to summarize the small-molecule drugs that were developed based on the pathogenesis and gives a deeper understanding of the AD. We hope that it could help scientists find new and better treatments to gradually conquer the problems related to AD in future.<\/jats:p>","DOI":"10.3389\/fnagi.2022.1019412","type":"journal-article","created":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T09:47:56Z","timestamp":1667296076000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":51,"title":["Small-molecule drugs development for Alzheimer's disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Weiwei","family":"Yao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinfei","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,11,1]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer's disease\u2013a randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci"},{"key":"B2","doi-asserted-by":"publisher","first-page":"473","DOI":"10.2174\/156720507781788882","article-title":"Alzhemed: a potential treatment for Alzheimer's disease","volume":"4","author":"Aisen","year":"2007","journal-title":"Curr. Alzheimer Res"},{"key":"B3","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.bcp.2004.11.015","article-title":"Reductions in \u03b2-amyloid concentrations in vivo by the \u03b3-secretase inhibitors BMS-289948 and BMS-299897","volume":"69","author":"Anderson","year":"2005","journal-title":"Biochem. Pharmacol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1146\/annurev-pathol-052016-100127","article-title":"The varied roles of notch in cancer","volume":"12","author":"Aster","year":"2017","journal-title":"Annu. Rev. Pathol"},{"key":"B5","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1111\/j.1749-6632.2001.tb03654.x","article-title":"Antihistamine agent dimebon as a novel neuroprotector and a cognition enhancer","volume":"939","author":"Bachurin","year":"2001","journal-title":"Ann. NY Acad. Sci."},{"key":"B6","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1111\/j.1471-4159.2004.02425.x","article-title":"Regulation of protein kinase C by the anti-Parkinson drug, MAO-B inhibitor, rasagiline and its derivatives, in vivo","volume":"89","author":"Bar-Am","year":"2004","journal-title":"J. Neurochem"},{"key":"B7","doi-asserted-by":"publisher","first-page":"187","DOI":"10.22270\/jddt.v10i1-s.3866","article-title":"Physostigmine: a plant alkaloid isolated from Physostigma venenosum: a review on pharmacokinetics, pharmacological and toxicological activities","volume":"10","author":"Batiha","year":"2020","journal-title":"J. Drug Deliv. Therap."},{"key":"B8","doi-asserted-by":"publisher","first-page":"303","DOI":"10.3233\/JAD-2008-15213","article-title":"Why do so many drugs for alzheimer's disease fail in development? Time for new methods and new practices?","volume":"15","author":"Becker","year":"2008","journal-title":"J. Alzheimer's Dis."},{"key":"B9","doi-asserted-by":"publisher","first-page":"3286","DOI":"10.1093\/brain\/awx243","article-title":"Tau pathology and neurodegeneration contribute to cognitive impairment in Alzheimer's disease","volume":"140","author":"Bejanin","year":"2017","journal-title":"Brain"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2013.08.244","article-title":"P4\u2013411: clinical study of E2609, a novel BACE1 inhibitor, demonstrates target engagement and inhibition of BACE1 activity in CSF","author":"Bernier","year":"2013","journal-title":"Alzheimers Dement."},{"key":"B11","doi-asserted-by":"publisher","first-page":"12657","DOI":"10.1002\/chem.201500888","article-title":"Combined experimental and simulation studies suggest a revised mode of action of the anti-alzheimer disease drug NQ-Trp","volume":"21","author":"Berthoumieu","year":"2015","journal-title":"Chem. Eur. J"},{"key":"B12","doi-asserted-by":"publisher","first-page":"e332","DOI":"10.1038\/tp.2013.97","article-title":"Latrepirdine: molecular mechanisms underlying potential therapeutic roles in Alzheimer's and other neurodegenerative diseases","volume":"3","author":"Bharadwaj","year":"2013","journal-title":"Transl. Psychiatry"},{"key":"B13","doi-asserted-by":"publisher","first-page":"123","DOI":"10.3233\/JAD-142421","article-title":"Nasal application of the galantamine pro-drug memogain slows down plaque deposition and ameliorates behavior in 5X familial Alzheimer's disease mice","volume":"46","author":"Bhattacharya","year":"2015","journal-title":"J. Alzheimer's Dis"},{"key":"B14","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.2337\/diacare.27.7.1660","article-title":"The effect of pioglitazone on peroxisome proliferator-activated receptor-\u03b3 target genes related to lipid storage in vivo","volume":"27","author":"Bogacka","year":"2004","journal-title":"Diabetes Care"},{"key":"B15","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1016\/S1474-4422(21)00043-0","article-title":"Safety and efficacy of pioglitazone for the delay of cognitive impairment in people at risk of Alzheimer's disease (TOMMORROW): a prognostic biomarker study and a phase 3, randomised, double-blind, placebo-controlled trial","volume":"20","author":"Burns","year":"2021","journal-title":"Lancet Neurol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jalz.2016.06.653","article-title":"O4-08-05: Azeliragon phase 2B survival analysis supports beneficial effects on delaying time to cognitive deterioration in patients with mild Alzheimer's disease","author":"Burstein","year":"2016","journal-title":"Alzheimers Dement."},{"key":"B17","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/1471-2377-14-12","article-title":"Effect of TTP488 in patients with mild to moderate Alzheimer's disease","volume":"14","author":"Burstein","year":"2014","journal-title":"BMC Neurol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"149","DOI":"10.14283\/jpad.2018.18","article-title":"Development of azeliragon, an oral small molecule antagonist of the receptor for advanced glycation endproducts, for the potential slowing of loss of cognition in mild Alzheimer's disease","volume":"5","author":"Burstein","year":"2018","journal-title":"J. Prev. Alzheimers Dis"},{"key":"B19","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1016\/j.neuron.2006.01.020","article-title":"M1 receptors play a central role in modulating AD-like pathology in transgenic mice","volume":"49","author":"Caccamo","year":"2006","journal-title":"Neuron"},{"key":"B20","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.jemermed.2018.02.019","article-title":"Safety and effectiveness of physostigmine: a 10-year retrospective review: Arens AM, Shah K, Al-Abri S, et al. Clin Toxicol 2018;56(2):101\u2013107","volume":"54","author":"Califf","year":"2018","journal-title":"J. Emerg. Med."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1021\/cn500148z","article-title":"The role of tau oligomers in the onset of Alzheimer's disease neuropathology","volume":"5","author":"C\u00e1rdenas-Aguayo","year":"2014","journal-title":"ACS Chem. Neurosci"},{"key":"B22","doi-asserted-by":"publisher","first-page":"775","DOI":"10.1096\/fj.10-167213","article-title":"\u03b2-Secretase inhibitor GRL-8234 rescues age-related cognitive decline in APP transgenic mice","volume":"25","author":"Chang","year":"2011","journal-title":"FASEB J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"CD009524","DOI":"10.1002\/14651858.CD009524.pub2","article-title":"Latrepirdine for Alzheimer's disease","volume":"4","author":"Chau","year":"2015","journal-title":"Cochrane Datab. Syst. Rev."},{"key":"B24","doi-asserted-by":"publisher","first-page":"CD001499","DOI":"10.1002\/14651858.cd001499","article-title":"Physostigmine for Alzheimer's disease","volume":"2","author":"Coelho","year":"2001","journal-title":"Cochrane Datab. Syst. Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/s41582-018-0013-z","article-title":"Tau-targeting therapies for Alzheimer disease","volume":"14","author":"Congdon","year":"2018","journal-title":"Nat. Rev. Neurol."},{"key":"B26","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1001\/jamaneurol.2015.0607","article-title":"Targeting prodromal Alzheimer disease with avagacestat: a randomized clinical trial","volume":"72","author":"Coric","year":"2015","journal-title":"JAMA Neurol"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1001\/archneurol.2012.2194","article-title":"Safety and tolerability of the \u03b3-secretase inhibitor avagacestat in a phase 2 study of mild to moderate Alzheimer disease","volume":"69","author":"Coric","year":"2012","journal-title":"Arch. Neurol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1016\/j.neubiorev.2011.03.001","article-title":"Revisiting the cholinergic hypothesis in the development of Alzheimer's disease","volume":"35","author":"Craig","year":"2011","journal-title":"Neurosci. Biobehav. Rev."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1126\/science.1217697","article-title":"ApoE-directed therapeutics rapidly clear \u03b2-amyloid and reverse deficits in AD mouse models","volume":"335","author":"Cramer","year":"2012","journal-title":"Science"},{"key":"B30","doi-asserted-by":"publisher","first-page":"3197","DOI":"10.1021\/bi400377p","article-title":"Development and mechanism of \u03b3-secretase modulators for Alzheimer's disease","volume":"52","author":"Crump","year":"2013","journal-title":"Biochemistry"},{"key":"B31","doi-asserted-by":"publisher","first-page":"e12050","DOI":"10.1002\/trc2.12050","article-title":"Alzheimer's disease drug development pipeline: 2020","volume":"6","author":"Cummings","year":"2020","journal-title":"Alzheimers Dement."},{"key":"B32","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1080\/14737175.2016.1175303","article-title":"Huperzine A as a neuroprotective and antiepileptic drug: a review of preclinical research","volume":"16","author":"Damar","year":"2016","journal-title":"Exp. Rev. Neurotherap."},{"key":"B33","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1586\/14737175.2015.995639","article-title":"Safety and clinical effects of EVP-6124 in subjects with Alzheimer's disease currently or previously receiving an acetylcholinesterase inhibitor medication","volume":"15","author":"Deardorff","year":"2015","journal-title":"Expert Rev. Neurother"},{"key":"B34","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13195-015-0121-6","article-title":"Peripheral and central effects of \u03b3-secretase inhibition by semagacestat in Alzheimer's disease","volume":"7","author":"Doody","year":"2015","journal-title":"Alzheimers Res. Ther"},{"key":"B35","doi-asserted-by":"publisher","first-page":"1109","DOI":"10.3233\/JAD-150834","article-title":"AZD3293: A novel, orally active BACE1 inhibitor with high potency and permeability and markedly slow off-rate kinetics","volume":"50","author":"Eketj\u00e4ll","year":"2016","journal-title":"J. Alzheimer's Dis."},{"key":"B36","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s00109-007-0156-7","article-title":"Properties of scyllo\u2013inositol as a therapeutic treatment of AD-like pathology","volume":"85","author":"Fenili","year":"2007","journal-title":"J. Mol. Med."},{"key":"B37","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jalz.2013.04.083","article-title":"O1\u201306\u201305: The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease","volume":"9","author":"Forman","year":"2013","journal-title":"Alzheimers Dement."},{"key":"B38","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1016\/j.jalz.2012.05.1900","article-title":"P4-196: The novel BACE inhibitor MK-8931 dramatically lowers cerebrospinal fluid A\u03b2 peptides in healthy subjects following single- and multiple-dose administration","volume":"8","author":"Forman","year":"2012","journal-title":"Alzheimers Dement."},{"key":"B39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.neuint.2005.08.012","article-title":"T-817MA, a novel neurotrophic agent, improves sodium nitroprusside-induced mitochondrial dysfunction in cortical neurons","volume":"48","author":"Fukushima","year":"2006","journal-title":"Neurochem. Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/j.bbrc.2011.03.091","article-title":"T-817MA, a neuroprotective agent, attenuates the motor and cognitive impairments associated with neuronal degeneration in P301L tau transgenic mice","volume":"407","author":"Fukushima","year":"2011","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e0214942","DOI":"10.1371\/journal.pone.0214942","article-title":"GTS-21 has cell-specific anti-inflammatory effects independent of \u03b17 nicotinic acetylcholine receptors","volume":"14","author":"Garg","year":"2019","journal-title":"PLoS ONE"},{"key":"B42","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1016\/S0140-6736(16)31275-2","article-title":"Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial","volume":"388","author":"Gauthier","year":"2016","journal-title":"Lancet"},{"key":"B43","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Arch. Neurol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"6765","DOI":"10.1039\/C3CS60460H","article-title":"BACE1 (\u03b2-secretase) inhibitors for the treatment of Alzheimer's disease","volume":"43","author":"Ghosh","year":"2014","journal-title":"Chem. Soc. Rev."},{"key":"B45","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1021\/ml1000239","article-title":"Discovery and evaluation of BMS-708163, a potent, selective and orally bioavailable \u03b3-secretase inhibitor","volume":"1","author":"Gillman","year":"2010","journal-title":"ACS Med. Chem. Lett"},{"key":"B46","doi-asserted-by":"publisher","first-page":"29639","DOI":"10.1074\/jbc.R800016200","article-title":"Structural classification of toxic amyloid oligomers","volume":"283","author":"Glabe","year":"2008","journal-title":"J. Biol. Chem"},{"key":"B47","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.expneurol.2009.07.035","article-title":"Targeting A\u03b2 and tau in Alzheimer's disease, an early interim report","volume":"223","author":"Golde","year":"2010","journal-title":"Exp. Neurol"},{"key":"B48","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jalz.2009.04.287","article-title":"P1-279: NIC5-15 as a treatment for Alzheimer's: safety, pharmacokinetics and clinical variables","volume":"5","author":"Grossman","year":"2009","journal-title":"Alzheimers Dement."},{"key":"B49","doi-asserted-by":"publisher","first-page":"373","DOI":"10.2174\/0929867321666141106122628","article-title":"Recent development of multifunctional agents as potential drug candidates for the treatment of Alzheimer's disease","volume":"22","author":"Guzior","year":"2015","journal-title":"Curr. Med. Chem."},{"key":"B50","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/nrm2101","article-title":"Soluble protein oligomers in neurodegeneration: lessons from the Alzheimer's amyloid \u03b2-peptide","volume":"8","author":"Haass","year":"2007","journal-title":"Nat. Rev. Mol. Cell Biol"},{"key":"B51","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.biopsych.2020.02.001","article-title":"The \u03b2-secretase BACE1 in Alzheimer's disease","volume":"89","author":"Hampel","year":"2021","journal-title":"Biol. Psychiatry"},{"key":"B52","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.molmed.2009.01.003","article-title":"Tau phosphorylation: the therapeutic challenge for neurodegenerative disease","volume":"15","author":"Hanger","year":"2009","journal-title":"Trends Mol. Med."},{"key":"B53","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1126\/science.1072994","article-title":"The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics","volume":"297","author":"Hardy","year":"2002","journal-title":"Science"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1517\/14656560903044982","article-title":"Development of semagacestat (LY450139), a functional \u03b3-secretase inhibitor, for the treatment of Alzheimer's disease","volume":"10","author":"Henley","year":"2009","journal-title":"Expert Opin. Pharmacother"},{"key":"B55","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.2165\/11595870-000000000-00000","article-title":"Current and emerging drug treatment options for Alzheimer's disease","volume":"71","author":"Herrmann","year":"2011","journal-title":"Drugs"},{"key":"B56","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1007\/s40263-018-0554-0","article-title":"Discovery and identification of an endogenous metabolite of tramiprosate and its prodrug ALZ-801 that inhibits beta amyloid oligomer formation in the human brain","volume":"32","author":"Hey","year":"","journal-title":"CNS Drugs"},{"key":"B57","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical pharmacokinetics and safety of ALZ-801, a novel prodrug of tramiprosate in development for the treatment of Alzheimer's disease","volume":"57","author":"Hey","year":"","journal-title":"Clin. Pharmacokin."},{"key":"B58","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1124\/jpet.117.240614","article-title":"Glutaminyl cyclase inhibitor PQ912 improves cognition in mouse models of Alzheimer's disease\u2014studies on relation to effective target occupancy","volume":"362","author":"Hoffmann","year":"2017","journal-title":"J. Pharmacol. Exp. Therap"},{"key":"B59","doi-asserted-by":"publisher","first-page":"11791","DOI":"10.3390\/ijms222111791","article-title":"Combination of the glutaminyl cyclase inhibitor PQ912 (varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain a\u03b2 pathology in transgenic mice","volume":"22","author":"Hoffmann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"B60","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1111\/j.1365-2990.2012.01307.x","article-title":"Review: systemic inflammation and Alzheimer's disease","volume":"39","author":"Holmes","year":"2013","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"B61","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1021\/cn200124u","article-title":"ACS chemical neuroscience molecule spotlight on begacestat (GSI-953)","volume":"3","author":"Hopkins","year":"2012","journal-title":"ACS Chem. Neurosci"},{"key":"B62","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1007\/s12035-016-0117-7","article-title":"A mitocentric view of Alzheimer's disease","volume":"54","author":"Hu","year":"2017","journal-title":"Mol. Neurobiol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.phymed.2016.03.009","article-title":"The effect of ethyl acetate extract from persimmon leaves on Alzheimer's disease and its underlying mechanism","volume":"23","author":"Huang","year":"2016","journal-title":"Phytomedicine"},{"key":"B64","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1111\/j.1476-5381.2008.00097.x","article-title":"CHF5074, a novel \u03b3-secretase modulator, attenuates brain \u03b2-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease","volume":"156","author":"Imbimbo","year":"2009","journal-title":"Br. J. Pharmacol"},{"key":"B65","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1080\/10543400802609805","article-title":"An adaptive first in man dose-escalation study of NGX267: statistical, clinical, and operational considerations","volume":"19","author":"Ivanova","year":"2009","journal-title":"J. Biopharm. Stat."},{"key":"B66","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1016\/j.arr.2013.06.003","article-title":"The role of polyphenols in the modulation of sirtuins and other pathways involved in Alzheimer's disease","volume":"12","author":"Jayasena","year":"2013","journal-title":"Ageing Res. Rev"},{"key":"B67","doi-asserted-by":"publisher","first-page":"41245","DOI":"10.1074\/jbc.M112.409110","article-title":"Discovery of AZD3839, a potent and selective BACE1 inhibitor clinical candidate for the treatment of alzheimer disease","volume":"287","author":"Jeppsson","year":"2012","journal-title":"J. Biol. Chem"},{"key":"B68","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1038\/aps.2013.7","article-title":"Phase I study on the pharmacokinetics and tolerance of ZT-1, a prodrug of huperzine A, for the treatment of Alzheimer's disease","volume":"34","author":"Jia","year":"2013","journal-title":"Acta Pharmacol. Sin."},{"key":"B69","doi-asserted-by":"publisher","first-page":"363ra150","DOI":"10.1126\/scitranslmed.aad9704","article-title":"The BACE1 inhibitor verubecestat (MK-8931) reduces CNS \u03b2-amyloid in animal models and in Alzheimer's disease patients","volume":"8","author":"Kennedy","year":"2016","journal-title":"Sci. Transl. Med"},{"key":"B70","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1111\/j.1476-5381.2009.00141.x","article-title":"T-817MA, a neurotrophic agent, ameliorates the deficits in adult neurogenesis and spatial memory in rats infused i.c.v. with amyloid-\u03b2 peptide","volume":"157","author":"Kimura","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"B71","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1093\/ndt\/gfn157","article-title":"Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats","volume":"23","author":"Ko","year":"2008","journal-title":"Nephrol. Dial. Transplant"},{"key":"B72","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.neuron.2010.08.018","article-title":"Modulation of \u03b3-secretase reduces \u03b2-amyloid deposition in a transgenic mouse model of Alzheimer's disease","volume":"67","author":"Kounnas","year":"2010","journal-title":"Neuron"},{"key":"B73","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.jalz.2012.05.237","article-title":"O1-06-05: First-in-human study of E2609, a novel BACE1 inhibitor, demonstrates prolonged reductions in plasma beta-amyloid levels after single dosing","volume":"8","author":"Lai","year":"2012","journal-title":"Alzheimers Dement."},{"key":"B74","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer's disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"B75","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1124\/jpet.110.167379","article-title":"Pharmacodynamics and pharmacokinetics of the \u03b3-secretase inhibitor PF-3084014","volume":"334","author":"Lanz","year":"2010","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"B76","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.4155\/fmc-2019-0151","article-title":"Recent tau-targeted clinical strategies for the treatment of Alzheimer's disease","volume":"11","author":"Lee","year":"2019","journal-title":"Future Med. Chem"},{"key":"B77","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1016\/j.brainresbull.2012.11.003","article-title":"\u03b17 nicotinic acetylcholine receptors and their role in cognition","volume":"93","author":"Lendvai","year":"2013","journal-title":"Brain Res. Bull."},{"key":"B78","doi-asserted-by":"publisher","first-page":"6046","DOI":"10.1039\/C6RA26737H","article-title":"Two decades of new drug discovery and development for Alzheimer's disease","volume":"7","author":"Liu","year":"2017","journal-title":"RSC Adv."},{"key":"B79","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/ADR-210296","article-title":"Phase II (NAVIGATE-AD study) results of LY3202626 effects on patients with mild Alzheimer's disease dementia","volume":"5","author":"Lo","year":"2021","journal-title":"J. Alzheimer's Dis. Rep."},{"key":"B80","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.trci.2015.08.002","article-title":"A phase 1 study to evaluate the safety and pharmacokinetics of PQ912, a glutaminyl cyclase inhibitor, in healthy subjects","volume":"1","author":"Lues","year":"2015","journal-title":"Alzheimers Dement"},{"key":"B81","doi-asserted-by":"publisher","first-page":"5766","DOI":"10.1523\/jneurosci.1004-07.2007","article-title":"NP031112, a thiadiazolidinone compound, prevents inflammation and neurodegeneration under excitotoxic conditions: potential therapeutic role in brain disorders","volume":"27","author":"Luna-Medina","year":"2007","journal-title":"J. Neurosci"},{"key":"B82","first-page":"177","article-title":"Scyllo-inositol, preclinical, and clinical data for alzheimer's disease,","volume-title":"Advances in Pharmacology","author":"Ma","year":"2012"},{"key":"B83","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s12031-009-9269-5","article-title":"Memogain is a galantamine pro-drug having dramatically reduced adverse effects and enhanced efficacy","volume":"40","author":"Maelicke","year":"2010","journal-title":"J. Mol. Neurosci"},{"key":"B84","doi-asserted-by":"publisher","first-page":"211","DOI":"10.3233\/jad-2008-15207","article-title":"Cell signaling pathways and iron chelation in the neurorestorative activity of green tea polyphenols: special reference to epigallocatechin gallate (EGCG)","volume":"15","author":"Mandel","year":"2008","journal-title":"J. Alzheimer's Dis"},{"key":"B85","doi-asserted-by":"publisher","first-page":"614","DOI":"10.3389\/fneur.2020.00614","article-title":"A review on tramiprosate (homotaurine) in Alzheimer's disease and other neurocognitive disorders","volume":"11","author":"Manzano","year":"2020","journal-title":"Front. Neurol"},{"key":"B86","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1124\/jpet.109.152975","article-title":"Begacestat (GSI-953): a novel, selective thiophene sulfonamide inhibitor of amyloid precursor protein \u03b3-secretase for the treatment of Alzheimer's disease","volume":"331","author":"Martone","year":"2009","journal-title":"J. Pharmacol. Exp. Therap."},{"key":"B87","first-page":"27","article-title":"Action of dimebon on histamine receptors","volume":"46","author":"Matveeva","year":"1983","journal-title":"Farmakol Toksikol."},{"key":"B88","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1126\/science.1197623","article-title":"Decreased clearance of CNS \u03b2-amyloid in Alzheimer's disease","volume":"330","author":"Mawuenyega","year":"2010","journal-title":"Science"},{"key":"B89","doi-asserted-by":"publisher","first-page":"16507","DOI":"10.1523\/jneurosci.3647-11.2011","article-title":"Robust central reduction of amyloid-\u03b2 in humans with an orally available, non-peptidic \u03b2-secretase inhibitor","volume":"31","author":"May","year":"2011","journal-title":"J. Neurosci"},{"key":"B90","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1523\/jneurosci.4129-14.2015","article-title":"The potent BACE1 inhibitor LY2886721 elicits robust central a\u03b2 pharmacodynamic responses in mice, dogs, and humans","volume":"35","author":"May","year":"2015","journal-title":"J. Neurosci"},{"key":"B91","doi-asserted-by":"publisher","first-page":"8076","DOI":"10.1021\/acs.jmedchem.1c00489","article-title":"Discovery and early clinical development of LY3202626, a low-dose, CNS-penetrant BACE inhibitor","volume":"64","author":"McKinzie","year":"2021","journal-title":"J. Med. Chem"},{"key":"B92","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1021\/cn300110c","article-title":"Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo","volume":"3","author":"Morales-Garcia","year":"2012","journal-title":"ACS Chem. Neurosci"},{"key":"B93","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/nrd.2016.281","article-title":"Alzheimer amyloid hypothesis lives on","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat. Rev. Drug Discov"},{"key":"B94","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1093\/toxsci\/kft224","article-title":"E2012-induced cataract and its predictive biomarkers","volume":"137","author":"Nakano-Ito","year":"2013","journal-title":"Toxicol. Sci."},{"key":"B95","doi-asserted-by":"publisher","first-page":"e9316","DOI":"10.15252\/emmm.201809316","article-title":"The BACE-1 inhibitor CNP520 for prevention trials in Alzheimer's disease","volume":"10","author":"Neumann","year":"2018","journal-title":"EMBO Mol. Med."},{"key":"B96","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1002\/hipo.20281","article-title":"Ameliorative effects of a neuroprotective agent, T-817MA, on place learning deficits induced by continuous infusion of amyloid-\u03b2 peptide (1\u201340) in rats","volume":"17","author":"Nguyen","year":"2007","journal-title":"Hippocampus"},{"key":"B97","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s13195-020-00614-5","article-title":"Long-term safety and tolerability of atabecestat (JNJ-54861911), an oral BACE1 inhibitor, in early Alzheimer's disease spectrum patients: a randomized, double-blind, placebo-controlled study and a two-period extension study","volume":"12","author":"Novak","year":"2020","journal-title":"Alzheimers Res. Ther"},{"key":"B98","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2174\/156720512801322564","article-title":"N-methyl D-aspartate (NMDA) receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease","volume":"9","author":"Olivares","year":"2012","journal-title":"Curr. Alzheimer Res."},{"key":"B99","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1016\/j.neuroscience.2016.02.040","article-title":"Green tea compound epigallo-catechin-3-gallate (EGCG) increases neuronal survival in adult hippocampal neurogenesis in vivo and in vitro","volume":"322","author":"Ortiz-L\u00f3pez","year":"2016","journal-title":"Neuroscience"},{"key":"B100","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1016\/j.jalz.2009.07.110","article-title":"P4-331: Nic5-15: a novel natural gamma-secretase inhibitor that attenuates brain beta-amyloid content and improves cognition","volume":"5","author":"Pasinetti","year":"2009","journal-title":"Alzheimers Dement."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.2174\/1570159X19666211201094031","article-title":"BACE1: a key regulator in Alzheimer's disease progression and current development of its inhibitors","volume":"20","author":"Patel","year":"2022","journal-title":"Curr. Neuropharmacol."},{"key":"B102","doi-asserted-by":"publisher","first-page":"2263","DOI":"10.1021\/acs.jmedchem.9b01034","article-title":"Discovery of AM-6494: a potent and orally efficacious \u03b2-site amyloid precursor protein cleaving enzyme 1 (BACE1) inhibitor with in vivo selectivity over BACE2","volume":"63","author":"Pettus","year":"2020","journal-title":"J. Med. Chem."},{"key":"B103","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3233\/JAD-180145","article-title":"Alzheimer's Disease: advances in drug development","volume":"65","author":"Piton","year":"2018","journal-title":"J. Alzheimers Dis"},{"key":"B104","doi-asserted-by":"publisher","first-page":"9710","DOI":"10.1074\/jbc.M112.398602","article-title":"\u03b3-secretase modulator (GSM) photoaffinity probes reveal distinct allosteric binding sites on presenilin","volume":"288","author":"Pozdnyakov","year":"2013","journal-title":"J. Biol. Chem"},{"key":"B105","doi-asserted-by":"publisher","first-page":"166162","DOI":"10.1016\/j.bbadis.2021.166162","article-title":"Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer's disease and tauopathies","volume":"1867","author":"Pradeepkiran","year":"2021","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis"},{"key":"B106","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1016\/j.neuropharm.2011.10.024","article-title":"EVP-6124, a novel and selective \u03b17 nicotinic acetylcholine receptor partial agonist, improves memory performance by potentiating the acetylcholine response of \u03b17 nicotinic acetylcholine receptors","volume":"62","author":"Prickaerts","year":"2012","journal-title":"Neuropharmacology"},{"key":"B107","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.ymben.2021.06.011","article-title":"Metabolic engineering of Corynebacterium glutamicum for production of scyllo-inositol, a drug candidate against Alzheimer's disease","volume":"67","author":"Ramp","year":"2021","journal-title":"Metab. Eng."},{"key":"B108","doi-asserted-by":"publisher","first-page":"S499","DOI":"10.3233\/JAD-2010-100504","article-title":"Amyloid-\u03b2 and mitochondria in aging and Alzheimer's disease: implications for synaptic damage and cognitive decline","volume":"20","author":"Reddy","year":"2010","journal-title":"J. Alzheimers Dis"},{"key":"B109","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1056\/NEJMoa013128","article-title":"Memantine in moderate-to-severe Alzheimer's disease","volume":"348","author":"Reisberg","year":"2003","journal-title":"New Engl. J. Med."},{"key":"B110","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nrneurol.2011.2","article-title":"Epidemiology of Alzheimer disease","volume":"7","author":"Reitz","year":"2011","journal-title":"Nat. Rev. Neurol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1056\/nejm199101313240525","article-title":"Tacrine as a treatment for Alzheimer's dementia","volume":"324","author":"Relman","year":"1991","journal-title":"New Engl. J. Med."},{"key":"B112","doi-asserted-by":"publisher","first-page":"742","DOI":"10.2174\/13892037113149990144","article-title":"CHF5074 reduces biomarkers of neuroinflammation in patients with mild cognitive impairment: a 12-week, double-blind, placebo-controlled study","volume":"10","author":"Ross","year":"2013","journal-title":"Curr. Alzheimer Res"},{"key":"B113","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1097\/WAD.0b013e318204b550","article-title":"PF-04494700, an oral inhibitor of receptor for advanced glycation end products (RAGE), in Alzheimer disease","volume":"25","author":"Sabbagh","year":"2011","journal-title":"Alzheimer Dis. Assoc. Disord"},{"key":"B114","first-page":"243","article-title":"Chapter Ten\u2014Neurotrophins: role in placental growth and development,","volume-title":"Vitamins and Hormones","author":"Sahay","year":"2017"},{"key":"B115","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1212\/WNL.0b013e3182309fa5","article-title":"A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease","volume":"77","author":"Salloway","year":"2011","journal-title":"Neurology"},{"key":"B116","doi-asserted-by":"publisher","first-page":"666958","DOI":"10.3389\/fnins.2021.666958","article-title":"Reassessment of pioglitazone for Alzheimer's disease","volume":"15","author":"Saunders","year":"2021","journal-title":"Front. Neurosci"},{"key":"B117","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1186\/s13195-018-0431-6","article-title":"Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer's disease: results of a randomized, double-blind, placebo-controlled phase 2a study","volume":"10","author":"Scheltens","year":"2018","journal-title":"Alzheimer's Res. Therapy"},{"key":"B118","doi-asserted-by":"publisher","first-page":"1330","DOI":"10.1001\/jamaneurol.2019.1868","article-title":"Safety and efficacy of edonerpic maleate for patients with mild to moderate alzheimer disease: a phase 2 randomized clinical trial","volume":"76","author":"Schneider","year":"2019","journal-title":"JAMA Neurol."},{"key":"B119","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3389\/fnagi.2017.00083","article-title":"Tau oligomers: cytotoxicity, propagation, and mitochondrial damage","volume":"9","author":"Shafiei","year":"2017","journal-title":"Front. Aging Neurosci"},{"key":"B120","doi-asserted-by":"publisher","first-page":"525","DOI":"10.2174\/156720508786898451","article-title":"Oxidative stress signaling in Alzheimer's disease","volume":"5","author":"Su","year":"2008","journal-title":"Curr. Alzheimer Res."},{"key":"B121","doi-asserted-by":"publisher","first-page":"9346","DOI":"10.1021\/jm3009025","article-title":"Design and synthesis of \u03b2-site amyloid precursor protein cleaving enzyme (BACE1) inhibitors with in vivo brain reduction of \u03b2-amyloid peptides","volume":"55","author":"Swahn","year":"2012","journal-title":"J. Med. Chem"},{"key":"B122","doi-asserted-by":"publisher","first-page":"30538","DOI":"10.1074\/jbc.M114.600833","article-title":"Amyloid-\u03b2 pathology and APOE genotype modulate retinoid x receptor agonist activity in vivo","volume":"289","author":"Tai","year":"2014","journal-title":"J. Biol. Chem."},{"key":"B123","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1186\/s13195-020-00663-w","article-title":"Aducanumab, gantenerumab, BAN2401, and ALZ-801\u2014the first wave of amyloid-targeting drugs for Alzheimer's disease with potential for near term approval","volume":"12","author":"Tolar","year":"2020","journal-title":"Alzheimer's Res. Therapy"},{"key":"B124","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1016\/j.jalz.2019.09.075","article-title":"The path forward in Alzheimer's disease therapeutics: Reevaluating the amyloid cascade hypothesis","volume":"16","author":"Tolar","year":"2019","journal-title":"Alzheimers Dement."},{"key":"B125","doi-asserted-by":"publisher","first-page":"5253","DOI":"10.1080\/07391102.2020.1869099","article-title":"Unravelling the molecular basis of AM-6494 high potency at BACE1 in Alzheimer's disease: an integrated dynamic interaction investigation","volume":"40","author":"Ugbaja","year":"2020","journal-title":"J. Biomol. Struct. Dyn."},{"key":"B126","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/1755-8794-7-35","article-title":"A systems biology approach to understand the pathophysiological mechanisms of cardiac pathological hypertrophy associated with rosiglitazone","volume":"7","author":"Verschuren","year":"2014","journal-title":"BMC Med. Genomics"},{"key":"B127","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cbi.2008.05.038","article-title":"The neuroprotective effect of ladostigil against hydrogen peroxide-mediated cytotoxicity","volume":"175","author":"Weinreb","year":"2008","journal-title":"Chem. Biol. Interact."},{"key":"B128","first-page":"219","article-title":"Pharmacological evaluation of phenyl-carbamates as CNS-selective acetylcholinesterase inhibitors","volume":"43","author":"Weinstock","year":"1994","journal-title":"J. Neural Transm. Suppl"},{"key":"B129","doi-asserted-by":"publisher","first-page":"1201","DOI":"10.3233\/JAD-2010-101311","article-title":"Phenserine efficacy in Alzheimer's disease","volume":"22","author":"Winblad","year":"2010","journal-title":"J. Alzheimer's Dis."},{"key":"B130","doi-asserted-by":"publisher","first-page":"158","DOI":"10.2174\/156720508783954767","article-title":"\u03b3-secretase inhibition and modulation for Alzheimer's disease","volume":"5","author":"Wolfe","year":"2008","journal-title":"Curr. Alzheimer Res"},{"key":"B131","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.mito.2019.07.003","article-title":"Mitochondrial dysfunction in neurodegenerative diseases and drug targets via apoptotic signaling","volume":"49","author":"Wu","year":"2019","journal-title":"Mitochondrion"},{"key":"B132","doi-asserted-by":"publisher","first-page":"128444","DOI":"10.1016\/j.bmcl.2021.128444","article-title":"Design, synthesis and anti-TNBC activity of Azeliragon triazole analogues","volume":"54","author":"Xie","year":"2021","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"B133","doi-asserted-by":"publisher","first-page":"e74916","DOI":"10.1371\/journal.pone.0074916","article-title":"Huperzine A for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials","volume":"8","author":"Yang","year":"2013","journal-title":"PLoS ONE"},{"key":"B134","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.cell.2020.11.049","article-title":"Structural basis of \u03b3-secretase inhibition and modulation by small molecule drugs","volume":"184","author":"Yang","year":"2021","journal-title":"Cell"},{"key":"B135","doi-asserted-by":"publisher","first-page":"1674","DOI":"10.1096\/fj.02-0198fje","article-title":"Involvement of MAP kinase in the regulation of amyloid precursor protein processing by novel cholinesterase inhibitors derived from rasagiline","volume":"16","author":"Yogev-Falach","year":"2002","journal-title":"FASEB J"},{"key":"B136","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1111\/j.1447-0594.2011.00827","article-title":"3-(2,4-Dimethoxybenzylidene)-anabaseine: a promising candidate drug for Alzheimer's disease?","volume":"12","author":"Zawieja","year":"2012","journal-title":"Geriatr. Gerontol. Int."}],"container-title":["Frontiers in Aging Neuroscience"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.1019412\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T09:48:04Z","timestamp":1667296084000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnagi.2022.1019412\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,1]]},"references-count":136,"alternative-id":["10.3389\/fnagi.2022.1019412"],"URL":"https:\/\/doi.org\/10.3389\/fnagi.2022.1019412","relation":{},"ISSN":["1663-4365"],"issn-type":[{"value":"1663-4365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,1]]},"article-number":"1019412"}}